The pharmaceutical contract manufacturing market is projected to grow at an annualized rate of ~7%, till 2030
Roots
Analysis has announced the addition
of “Pharmaceutical Contract Manufacturing Market
(3rd Edition), 2021-2030”
report to its list of offerings.
To order this 510 page
report, which features 180+ figures and 175+ tables, please visit
Key Market Insights
§ Presently, close to
500 players claim to have the required capabilities to provide a wide array of
services for pharmaceutical drug development across preclinical, clinical and
commercial scales.
§ The market is
characterized by the presence of both established players and new entrants that
offer end-to-end services, ranging from pre-formulation studies to regulatory
support.
§ With more than 1,350 facilities,
pharmaceutical contract manufacturers have established global presence;
majority of these players are based in emerging geographies.
§ In order to meet the
rising demand for APIs and finished products, CMOs have made elaborate
investments to expand their existing capacities and capabilities; this trend is
most pronounced in the US and India.
§ In pursuit of a competitive edge and to
eventually establish themselves as one-stop shops, stakeholders are actively
consolidating their capabilities related to small molecule manufacturing
through mergers and acquisitions.
§ The installed global
contract manufacturing capacity, spread across various geographies, is
presently estimated to be close to 160 million litres.
§ Though existing capacity is sufficient to
meet the current annual demand of small molecule APIs, we anticipate that
stakeholders will continue to invest in building incremental capacity to meet
the long-term demand.
§ Increase in number of
approvals and manufacturing complexity related to small molecule drugs is
anticipated to drive the growth in contract manufacturing market at a CAGR of 6.5%, till 2030.
§ The projected future
opportunity is likely to be well-distributed, in terms of service revenues,
across different types of packaging forms, end-users and key geographical
regions.
For more information, please visit https://www.rootsanalysis.com/reports/view_document/pharmaceutical-contract-manufacturing-market/191.html or email sales@rootsanalysis.com
Table of Contents
1. PREFACE
1.1. Scope
of the Report
1.2. Research
Methodology
1.3. Key
Questions Answered
1.4. Chapter
Outlines
2. EXECUTIVE
SUMMARY
3. INTRODUCTION
3.1. Chapter
Overview
3.2. Types of
Manufacturers
3.3. Overview
of Pharmaceutical Contract Manufacturing
3.4. Evolution
of Pharmaceutical Contract Manufacturing
3.4.1. Traditional
Pharmaceutical CMOs
3.4.2. Modern
Pharmaceutical CMOs
3.5. Need for
Outsourcing in the Pharmaceutical Industry
3.6. Recent
Trends in the Pharmaceutical Contract Manufacturing Industry
3.6.1. Tactical
Partnerships
3.6.2. Integrated
End-to-End Business Model
3.6.3. Software
Service Providers
3.7. Services
Offered by CMOs
3.8. Key Considerations
While Selecting a CMO Partner
3.9. Risks
and Challenges Associated with Outsourcing Pharmaceutical Manufacturing
Operations
4. REGULATORY LANDSCAPE FOR PHARMACEUTICAL
CONTRACT MANUFACTURERS
4.1. Chapter
Overview
4.2. Regulatory
Guidelines in North America
4.2.1. The US
Scenario
4.2.2. Canadian
Scenario
4.3. Regulatory
Guidelines in Europe
4.4. Regulatory
Guidelines in Asia-Pacific and Rest of the World
4.4.1. Chinese
Scenario
4.4.2. Indian
Scenario
4.4.3. Japanese
Scenario
4.4.4. South
Korean Scenario
4.4.5 Australian
Scenario
4.4.6. Brazilian
Scenario
4.5. Analysis
of Pharmaceutical CMOs by Approval Received from Regulatory Authorities
4.6. Regional
Summary of Regulatory Scenario (Bubble Analysis)
5. PHARMACEUTICAL
CMOs: CURRENT MARKET LANDSCAPE
5.1. Chapter
Overview
5.2. Pharmaceutical
CMOs: List of Industry Players
5.2.1. Analysis
by Year of Establishment
5.2.2. Analysis
by Company Size
5.2.3. Analysis
by Location of Headquarters
5.2.4. Analysis
by Type of Business Segment
5.2.5. Analysis
by Type of API Manufactured
5.2.6. Analysis
by Type of FDF Offered
5.2.7. Analysis
by Type of Molecule
5.2.8. Analysis
by Type of Service(s) Offered
5.2.9. Analysis
by Type of Primary Packaging Form Offered
5.2.10. Analysis
by Scale of Operation
5.2.11. Analysis
by Location of Manufacturing Facility
5.2.11.1 Pharmaceutical Contract
Manufacturing Facilities in North America
5.2.11.2 Pharmaceutical Contract
Manufacturing Facilities in Europe
5.2.11.3 Pharmaceutical Contract
Manufacturing Facilities in Asia-Pacific and Rest of the World
6. REGIONAL
CAPABILITY
6.1. Chapter
Overview
6.2. Key
Assumptions and Methodology
6.3. Regional
Capability Analysis of Pharmaceutical CMOs
6.3.1 Analysis
of CMOs based in North America
6.3.2. Analysis
of CMOs based in Europe
6.3.3. Analysis
of CMOs based in Asia-Pacific and Rest of the World
7. COMPANY
PROFILES
7.1. Chapter
Overview
7.2. Key
Benefits Key Benefits Offered by the One-Stop-Shop Model
7.3 Profiles
of Players Operating as One-Stop-Shops
7.4. North
America
7.4.1. AMRI
Global
7.4.1.1. Company
Overview
7.4.1.2. Service
Portfolio
7.4.1.3. Manufacturing
Capabilities and Facilities
7.4.1.4. Recent
Developments and Future Outlook
7.4.2. Altasciences
7.4.2.1. Company
Overview
7.4.2.2. Service
Portfolio
7.4.2.3. Manufacturing
Capabilities and Facilities
7.4.2.4. Recent
Developments and Future Outlook
7.4.3. Cambrex
7.4.3.1. Company
Overview
7.4.3.2. Service
Portfolio
7.4.3.3. Manufacturing
Capabilities and Facilities
7.4.3.4. Recent
Developments and Future Outlook
7.4.4. Catalent
7.4.4.1. Company
Overview
7.4.4.2. Financial
Information
7.4.4.3. Service
Portfolio
7.4.4.4. Manufacturing
Capabilities and Facilities
7.4.4.5. Recent
Developments and Future Outlook
7.4.5. DPT
Laboratories
7.4.5.1. Company
Overview
7.4.5.2. Service
Portfolio
7.4.5.3. Manufacturing
Capabilities and Facilities
7.4.5.4. Recent
Developments and Future Outlook
7.4.6. Thermo
Fisher Scientific
7.4.6.1. Company
Overview
7.4.6.2. Financial
Information
7.4.6.3. Service
Portfolio
7.4.6.4. Manufacturing
Capabilities and Facilities
7.4.6.5. Recent
Developments and Future Outlook
7.5. Europe
7.5.1. Aenova
Group
7.5.1.1. Company
Overview
7.5.1.2. Financial
Information
7.5.1.3. Service
Portfolio
7.5.1.4. Manufacturing
Capabilities and Facilities
7.5.1.5. Recent
Developments and Future Outlook
7.5.2. Almac
7.5.2.1. Company
Overview
7.5.2.2. Service
Portfolio
7.5.2.3. Recent
Developments and Future Outlook
7.5.3. Corden
Pharma
7.5.3.1. Company
Overview
7.5.3.2. Service
Portfolio
7.5.3.3. Manufacturing
Capabilities and Facilities
7.5.3.4. Recent
Developments and Future Outlook
7.5.4. Fresenius
Kabi
7.5.4.1. Company
Overview
7.5.4.2. Financial
Information
7.5.4.3. Service
Portfolio
7.5.4.4. Manufacturing
Capabilities and Facilities
7.5.4.5. Recent
Developments and Future Outlook
7.5.5. Glatt
7.5.5.1. Company
Overview
7.5.5.2. Service
Portfolio
7.5.5.3. Manufacturing
Capabilities and Facilities
7.5.5.4. Recent
Developments and Future Outlook
7.5.6. Hovione
7.5.6.1. Company
overview
7.5.6.2. Service Portfolio
7.5.6.3. Manufacturing
Capabilities and Facilities
7.5.6.4. Recent
Developments and Future Outlook
7.5.7. Recipharm
7.5.7.1. Company
Overview
7.5.7.2. Financial
Information
7.5.7.3. Service
Portfolio
7.5.7.4. Manufacturing
Capabilities and Facilities
7.5.7.5. Recent
Developments and Future Outlook
7.5.8. Siegfried
7.5.8.1. Company
Overview
7.5.8.2. Financial
Information
7.5.8.3. Service
Portfolio
7.5.8.4. Manufacturing
Capabilities and Facilities
7.5.8.5. Recent
Developments and Future Outlook
7.6. Asia-Pacific
and Rest of the World
7.6.1. CMIC
Group
7.6.1.1. Company
Overview
7.6.1.2. Financial
Information
7.6.1.3. Service
Portfolio
7.6.1.4. Recent
Developments and Future Outlook
7.6.2. Nectar
Lifesciences
7.6.2.1. Company
Overview
7.6.2.2. Financial
Information
7.6.2.3. Service
Portfolio
7.6.2.4. Manufacturing
Capabilities and Facilities
7.6.2.5. Recent
Developments and Future Outlook
7.6.3. Syngene
7.6.3.1. Company
Overview
7.6.3.2. Financial
Information
7.6.3.3. Service
Portfolio
7.6.3.4. Manufacturing
Capabilities and Facilities
7.6.3.5. Recent
Developments and Future Outlook
7.6.4. WuXi
AppTec
7.6.4.1. Company
Overview
7.6.4.2. Financial
Information
7.6.4.3. Service
Portfolio
7.6.4.4. Manufacturing
Capabilities and Facilities
7.6.4.5. Recent
Developments and Future Outlook
8. MAKE
VERSUS BUY DECISION FRAMEWORK
8.1. Chapter
Overview
8.2. Assumptions
and Key Parameters
8.3. Pharmaceutical
Contract Manufacturers: Make versus Buy Decision Making
8.3.1. Scenario
1
8.3.2. Scenario
2
8.3.3. Scenario
3
8.3.4. Scenario
4
8.4. Concluding
Remarks
9. MERGERS
AND ACQUISITIONS
9.1. Chapter
Overview
9.2. Merger
and Acquisition Models
9.3. Pharmaceutical
Contract Manufacturing: Mergers and Acquisitions
9.3.1. Cumulative
Year-wise Trend
9.3.2. Analysis
by Type of Agreement
9.3.3. Analysis
by Type of Acquisition
9.3.4. Analysis by Focus Area
9.3.5. Analysis by Type of Business Segment
9.3.6. Analysis
by Type of Service(s) Offered
9.3.7. Analysis
by Scale of Operation
9.3.8. Analysis
by Geography
9.3.9. Analysis
by Location of Manufacturing Facility
9.3.10. Most
Active Acquirers: Analysis by Number of Acquisitions
9.3.11. Analysis
by Key Value Drivers
9.3.11.1. Analysis by
Year of Acquisition and Key Value Drivers
9.4. Key
Acquisitions: Analysis by Deal Multiples
10. RECENT
EXPANSIONS
10.1. Chapter
Overview
10.2. Pharmaceutical
Contract Manufacturing Market: Expansions
10.2.1. Cumulative
Year-wise Distribution
10.2.2. Analysis
by Purpose of Expansion
10.2.3. Analysis
by Year and Purpose of Expansion
10.2.4. Analysis
by Type of Business Segment
10.2.5. Analysis
by Type of Molecule
10.2.6. Analysis
by Type of Service(s) Offered
10.2.7. Analysis
by Scale of Operation
10.2.8. Analysis
by Capital Invested
10.2.9. Analysis
by Location of Headquarters
10.2.10. Analysis by Purpose of
Expansion and Location of Headquarters
10.2.11. Analysis by Location of
Manufacturing Facility
10.2.12. Most Active Players:
Analysis by Number of Recent Expansions
11. CAPACITY
ANALYSIS
11.1. Chapter
Overview
11.2. Key Assumptions
and Methodology
11.3. Pharmaceutical
Contract Manufacturing: Global Production Capacity
11.3.1. Analysis
by Company Size
11.3.2. Analysis
by Scale of Operation
11.3.3. Analysis
by Location of Headquarters
11.3.3.1. Analysis of
Capacity Installed in North America
11.3.3.2. Analysis of
Capacity Installed in Europe
11.3.3.3. Analysis of
Capacity Installed in Asia-Pacific
11.4. Concluding
Remarks
12. DEMAND
ANALYSIS
12.1. Chapter
Overview
12.2. Key
Assumptions and Methodology
12.3. Overall
Annual Demand for Small Molecule APIs, 2021-2030
12.3.1. Analysis
by Scale of Operation
12.4. Correlation
Between Annual Demand and Capacity
13. MARKET
FORECAST
13.1. Chapter
Overview
13.2. Forecast
Methodology and Key Assumptions
13.3. Global
Pharmaceutical Contract Manufacturing Market, 2021-2030
13.3.1. Pharmaceutical Contract
Manufacturing Market, 2021 and 2030: Distribution by Business Segment
13.1.2. Pharmaceutical Contract
Manufacturing Market, 2021 and 2030: Distribution by Type of API Manufactured
13.1.3. Pharmaceutical Contract
Manufacturing Market, 2021 and 2030: Distribution by Type of FDF Offered
13.1.4. Pharmaceutical Contract
Manufacturing Market, 2021 and 2030: Distribution by Scale of Operation
13.1.5. Pharmaceutical Contract
Manufacturing Market, 2021 and 2030: Distribution by Type of Packaging Form
13.1.6. Pharmaceutical Contract
Manufacturing Market, 2021 and 2030: Distribution by Type of End-Users
13.1.7. Pharmaceutical Contract
Manufacturing Market, 2021 and 2030: Distribution by Geography
13.1.7.1. Pharmaceutical Contract
Manufacturing Market in North America, 2021-2030
13.1.7.1.1. Pharmaceutical Contract
Manufacturing Market in North America, 2021-2030: Distribution by Business
Segment
13.1.7.1.2. Pharmaceutical Contract
Manufacturing Market in North America, 2021-2030: Distribution by Type of API
Manufactured
13.1.7.1.3. Pharmaceutical Contract
Manufacturing Market in North America, 2021-2030: Distribution by Type of FDF
Offered
13.1.7.1.4. Pharmaceutical Contract
Manufacturing Market in North America, 2021-2030: Distribution by Scale of
Operation
13.1.7.1.5. Pharmaceutical Contract
Manufacturing Market in North America, 2021-2030: Distribution by Type of
Packaging Form
13.1.7.1.6. Pharmaceutical Contract
Manufacturing Market in North America, 2021-2030: Distribution by Type of
End-Users
13.1.7.2. Pharmaceutical Contract
Manufacturing Market in Europe, 2021-2030
13.1.7.2.1. Pharmaceutical Contract
Manufacturing Market in Europe, 2021-2030: Distribution by Business Segment
13.1.7.2.2. Pharmaceutical Contract
Manufacturing Market in Europe, 2021-2030: Distribution by Type of API
Manufactured
13.1.7.2.3. Pharmaceutical Contract
Manufacturing Market in Europe, 2021-2030: Distribution by Type of FDF Offered
13.1.7.2.4. Pharmaceutical Contract
Manufacturing Market in Europe, 2021-2030: Distribution by Scale of Operation
13.1.7.2.5. Pharmaceutical Contract
Manufacturing Market in Europe, 2021-2030: Distribution by Type of Packaging
Form
13.1.7.2.6. Pharmaceutical Contract
Manufacturing Market in Europe, 2021-2030: Distribution by Type of End-Users
13.1.7.3. Pharmaceutical Contract
Manufacturing Market in Asia-Pacific, 2021-2030
13.1.7.3.1. Pharmaceutical Contract
Manufacturing Market in Asia-Pacific, 2021-2030: Distribution by Business
Segment
13.1.7.3.2. Pharmaceutical Contract
Manufacturing Market in Asia-Pacific, 2021-2030: Distribution by Type of API
Manufactured
13.1.7.3.3. Pharmaceutical Contract
Manufacturing Market in Asia-Pacific, 2021-2030: Distribution by Type of FDF
Offered
13.1.7.3.4. Pharmaceutical Contract
Manufacturing Market in Asia-Pacific, 2021-2030: Distribution by Scale of
Operation
13.1.7.3.5. Pharmaceutical Contract
Manufacturing Market in Asia-Pacific, 2021-2030: Distribution by Type of
Packaging Form
13.1.7.3.6. Pharmaceutical Contract
Manufacturing Market in Asia-Pacific, 2021-2030: Distribution by Type of
End-Users
13.1.7.4. Pharmaceutical Contract
Manufacturing Market in Latin America, 2021-2030
13.1.7.4.1. Pharmaceutical Contract
Manufacturing Market in Latin America, 2021-2030: Distribution by Business
Segment
13.1.7.4.2. Pharmaceutical Contract
Manufacturing Market in Latin America, 2021-2030: Distribution by Type of API
Manufactured
13.1.7.4.3. Pharmaceutical Contract
Manufacturing Market in Latin America, 2021-2030: Distribution by Type of FDF
Offered
13.1.7.4.4. Pharmaceutical Contract
Manufacturing Market in Latin America, 2021-2030: Distribution by Scale of
Operation
13.1.7.4.5. Pharmaceutical Contract Manufacturing
Market in Latin America, 2021-2030: Distribution by Type of Packaging Form
13.1.7.4.6. Pharmaceutical Contract
Manufacturing Market in Latin America, 2021-2030: Distribution by Type of
End-Users
13.1.7.5. Pharmaceutical Contract
Manufacturing Market in Middle East and North Africa, 2021-2030
13.1.7.5.1. Pharmaceutical Contract
Manufacturing Market in Middle East and North Africa, 2021-2030: Distribution
by Business Segment
13.1.7.5.2. Pharmaceutical Contract
Manufacturing Market in Middle East and North Africa, 2021-2030: Distribution
by Type of API Manufactured
13.1.7.5.3. Pharmaceutical Contract
Manufacturing Market in Middle East and North Africa, 2021-2030: Distribution
by Type of FDF Offered
13.1.7.5.4. Pharmaceutical Contract
Manufacturing Market in Middle East and North Africa, 2021-2030: Distribution
by Scale of Operation
13.1.7.5.5. Pharmaceutical Contract
Manufacturing Market in Middle East and North Africa, 2021-2030: Distribution
by Type of Packaging Form
13.1.7.5.6. Pharmaceutical Contract
Manufacturing Market in Middle East and North Africa, 2021-2030: Distribution
by Type of End-Users
14. KEY
INSIGHTS
14.1. Chapter
Overview
14.2. Integrated
Contract Service Providers (Heat Map Analysis)
14.3. Analysis
by Geography
14.4. Analysis
by Geography, Company Size and Business Segment
15. SWOT
ANALYSIS
15.1. Chapter
Overview
15.2. Strengths
15.3. Weaknesses
15.4. Opportunities
15.5. Threats
15.6. Comparison
of SWOT Factors
16. CASE STUDY: COMPARISON OF SMALL AND LARGE
MOLECULES DRUGS / THERAPIES
16.1. Chapter
Overview
16.2. Small
Molecule and Large Molecule Drugs / Therapies
16.2.1. Comparison
of General Characteristics
16.2.2. Comparison
of Key Specifications
16.2.3. Comparison
of Manufacturing Processes
16.2.4. Comparison
of Key Manufacturing-related Challenges
17. CONCLUDING
REMARKS
18. EXECUTIVE
INSIGHTS
18.1. Chapter
Overview
18.2. Ajinomoto
Althea
18.2.1. Company
Snapshot
18.2.2. Interview Transcript: Scott
Goldstein, Ex - Director, Business Development, Drug Product Manufacturing
18.3. Bachem
18.3.1. Company
Snapshot
18.3.2. Interview
Transcript: Thomas Fruh, Ex - Chief Executive Officer
18.4. CiVentiChem
18.4.1. Company
Snapshot
18.4.2. Interview
Transcript: Bhaskar VenePalli, President and Chief Executive Officer
18.5. CordenPharma
18.5.1. Company
Snapshot
18.5.2. Interview
Transcript: Roberto Margartia, Director, Business Development
18.6. Helsinn
Group
18.6.1. Company
Snapshot
18.6.2. Interview
Transcript: Allison Vavala, Director, Commercial Development
18.7. Novasep
18.7.1. Company
Snapshot
18.7.2. Interview
Transcript: Kevin Daley, Director, Pharmaceuticals Marketing
18.8. Sovereign
Pharma
18.8.1. Company
Snapshot
18.8.2. Interview
Transcript: Piyush Desai, Director, Operations
18.9. Wavelength
Pharmaceuticals
18.9.1. Company
Snapshot
18.9.2. Interview
Transcript: Ilan Avni, Vice President Business Development, Marketing, and IP
19. APPENDIX
I: TABULATED DATA
20. APPENDIX
II: LIST OF COMPANIES AND ORGANIZATIONS
Contact Details
Roots Analysis Private Limited
Ben Johnson
+1 (415) 800 3415
+44 (122) 391 1091
Comments
Post a Comment